Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University,Shandong,Qingdao,China,266021
Man Wang, Fei Yu, Yuan Zhang. Current status and prospects of artificial intelligence in liver cancer management[J]. Intelligent Oncology, 2025, 1(3): 216-232.
DOI:
Man Wang, Fei Yu, Yuan Zhang. Current status and prospects of artificial intelligence in liver cancer management[J]. Intelligent Oncology, 2025, 1(3): 216-232.DOI: 10.1016/j.intonc.2025.06.003.
Current status and prospects of artificial intelligence in liver cancer management
Liver cancer is an extremely heterogeneous malignant tumor characterized by high morbidity and mortality rates. Despite significant advancements in cancer care
the outcomes of liver cancer patients remain poor. Artificial intelligence (AI) is a major discipline in computer science that attempts to simulate human intelligence using machines or systems. Owing to the availability of multidimensional databases and recent algorithmic advancements
AI offers tremendous potential to overcome current obstacles in oncology research and practice. There is a growing body of evidence suggesting that AI models enable pathologists to diagnose liver cancer more accurately
customize personalized therapies
and predict cancer prognosis. Therefore
the increasing adoption of AI is expected to improve healthcare accuracy and patients’ quality of life. However
only a few AI models are currently authorized for clinical use. This review outlines recent developments in research on the biomedical application of AI technology in liver cancer and discusses both the potential hurdles and future implications of employing AI for clinical cancer management
thereby providing insights for further research. Overall
the clinical implementation of AI technology is anticipated to induce a paradigm shift in medical oncology
leading to significant improvements in patient outcomes.
Abstract
Liver cancer is an extremely heterogeneous malignant tumor characterized by high morbidity and mortality rates. Despite significant advancements in cancer care
the outcomes of liver cancer patients remain poor. Artificial intelligence (AI) is a major discipline in computer science that attempts to simulate human intelligence using machines or systems. Owing to the availability of multidimensional databases and recent algorithmic advancements
AI offers tremendous potential to overcome current obstacles in oncology research and practice. There is a growing body of evidence suggesting that AI models enable pathologists to diagnose liver cancer more accurately
customize personalized therapies
and predict cancer prognosis. Therefore
the increasing adoption of AI is expected to improve healthcare accuracy and patients’ quality of life. However
only a few AI models are currently authorized for clinical use. This review outlines recent developments in research on the biomedical application of AI technology in liver cancer and discusses both the potential hurdles and future implications of employing AI for clinical cancer management
thereby providing insights for further research. Overall
the clinical implementation of AI technology is anticipated to induce a paradigm shift in medical oncology
leading to significant improvements in patient outcomes.
Analysis of key technologies and intelligent development trends for tumor surgery navigation platforms
Advancing precision oncology through hNQO1-activatable NIR-II probes: Integrating molecular imaging with artificial intelligence
Integrating multi-omic liquid biopsies and artificial intelligence: The next frontier in early cancer detection
Multimodal medical imaging AI for breast cancer diagnosis: A comprehensive review
Performance evaluation of artificial intelligence–assisted diagnostic tools for human papillomavirus–related cervical and anal cancers and their precancerous lesions: A systematic review and meta-analysis
Related Author
Li
Xia
Wu
Le
Ling
Shu
Analikwu
Egbewole
Related Institution
Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord 881373
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Shahrekord Branch, Shahrekord 881373
Department of Molecular Cell Biology, University of California, Merced CA
Santa Clara University, Santa Clara CA
Phase I Clinical Trial Research Ward, The Second Affiliated Hospital of Xi’an Jiaotong University